PFE stock sentiment todayPfizer Inc.
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
PFE
Pfizer Inc.Pfizer is a high-yield turnaround play grappling with a post-pandemic revenue cliff and high-stakes M&A integration.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for PFE. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by 'Comirnaty fatigue' and activist pressure from Starboard Value. Investors are skeptical of the $43B Seagen acquisition's ability to offset lost COVID-19 revenue in the near term, though the dividend remains a key attraction for value seekers.
- ·Activist investor pressure for cost-cutting
- ·Skepticism over oncology pipeline execution
- ·Management credibility regarding post-COVID guidance
Financial
Fundamentals are in a transition phase; while the balance sheet is leveraged following the Seagen deal, cash flows remain sufficient to cover the ~5.5% dividend yield. Growth is currently negative year-over-year but stabilizing.
- ·Forward P/E around 11x (below 5-year average)
- ·Dividend yield ~5.5%
- ·Net Debt/EBITDA elevated due to M&A
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·Insiders bought a net $2.9M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Patent cliffs for Eliquis and Vyndaqel later this decade
- ·Integration risks associated with the Seagen oncology portfolio
- ·Potential for dividend cuts if R&D returns fail to materialize
Peer temperature
How direct competitors stack up against PFE right now.
- HOTLLYEli Lilly
HOTTER — significantly higher valuation justified by dominant market share in the GLP-1 weight loss category where Pfizer has lagged.
See full analysis → - NEUTRALABVAbbVie
WARMER — more successful navigation of its primary patent cliff (Humira) compared to Pfizer’s COVID-revenue erosion.
See full analysis → - HOTMRKMerck & Co.
HOTTER — stronger current oncology performance led by Keytruda and a more focused, less leveraged balance sheet.
See full analysis →
- PFE+7.0%
- LLY+22.5%
- ABV—
- MRK+2.9%
Analyst price target
Consensus average of 20 analysts · median 29.00
Source: StockAnalysis.com · updated 2026-10-28
AI-generated analysis for informational purposes only. Not financial advice.